Key result
NOX inhibitors show potential for treating comorbid thrombosis and depression by targeting oxidative stress.
Why the study?
Comorbidities of cardiovascular disease and mental disorders like depression are prevalent, and understanding shared oxidative stress pathways such as NOX activation could facilitate new therapeutic approaches.
Do NOX inhibitors have therapeutic effects for the comorbidity of thrombosis and depression?
Do NOX inhibitors have therapeutic effects for the comorbidity of thrombosis and depression?
Targeting oxidative stress via NOX inhibitors represents a potential pharmacological strategy for managing the comorbidity of thrombosis and depression.
NOX inhibitors merit trial evaluation in thrombosis-depression comorbidity; leaves open therapeutic translation from preclinical data.
There is a complex interrelationship between the nervous system and the cardiovascular system. Comorbidities of cardiovascular diseases (CVD) with mental disorders, and vice versa, are prevalent. Adults with mental disorders such as anxiety and depression have a higher risk of developing CVD, and people with CVD have an increased risk of being diagnosed with mental disorders. Oxidative stress is one of the many pathways associated with the pathophysiology of brain and cardiovascular disease. Nicotinamide adenine dinucleotide phosphate oxidase (NOX) is one of the major generators of reactive oxygen species (ROS) in mammalian cells, as it is the enzyme that specifically produces superoxide. This review summarizes recent findings on the consequences of NOX activation in thrombosis and depression. It also discusses the therapeutic effects and pharmacological strategies of NOX inhibitors in CVD and brain disorders. A better comprehension of these processes could facilitate the development of new therapeutic approaches for the prevention and treatment of the comorbidity of thrombosis and depression.
No takes yet. Share an insight, caveat, or question.
Amadio et al. (2024) conducted a review in Thrombosis and depression comorbidity. NOX inhibitors was evaluated. NADPH-oxidase (NOX) inhibitors represent potential pharmacological strategies for the prevention and treatment of the comorbidity of thrombosis and depression by targeting oxidative stress pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: